echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Blood: Sickle-type blood disease therapy is also effective for COVID19

    Blood: Sickle-type blood disease therapy is also effective for COVID19

    • Last Update: 2021-03-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    January 29, 2021 // -- In a recent study, scientists found a way to reduce the risk of stroke in sickle cell patients, providing new ideas for potential treatment of inflammation and blood clotting symptoms caused by COVID-19, among others.
    the first time they have studied the use of immune cell proteins as an anti-inflammatory treatment to reduce blood clotting in patients with sickle cell disease.
    , published today in the journal Blood, explains how Ac2-26 peptides trigger a biological switch in immune cells in patients with sickle cell disease.
    professor Felicity Gavins, director of the Centre for Inflammation Research and Translational Medicine (CIRTM) at Brunel University in London, said: "Our goal is a pathophysiological immune response to help the body fight disease.
    it paves the way for new treatments to prevent thrombosis-inflammation-related diseases.
    " (Photo: www.pixabay.com) Like sickle cell disease, COVID-19 can trigger dangerous inflammation and thrombosis (blood clotting), leading to an increased risk of stroke, heart attack and pulmonary embolism (blood clotting in the lungs).
    because the risk of thrombosis and inflammation increases with age, the results can also have a significant impact on older people.
    the team studied the blood of 91 people between the ages of 18 and 52, half of whom had sickle cell disease.
    Ac2-26 peptides are present in immune cells or white blood cells in neutral granulocytes.
    trigger, Ac2-26 works in a way that is a protein and a subject that quickly calms inflammation.
    the role of the first responder, first appearing on the scene in an emergency.
    there, as if fishing, they threw out NET (neutrophil trap) to capture pathogens and protect the body.
    but sometimes NET can also aggravate disease.
    builds up and forms stents that are adhered to by other cells, such as plate plates.
    this build-up leads to inflammation of blood clots - a hallmark of many diseases and conditions, including sickle cell disease, chronic kidney disease, sepsis and cancer.
    This is the first study to show that peptide Ac2-26 can be used to alter the response of neutral granulocytes in patients with sickle cell disease, thereby losing the ability of neutral granulocytes to produce harmful NET, which can lead to thrombosis inflammation.
    Professor Gavins said: "These unique findings may stimulate not only sickle cell disease, but also drug discoveries for other diseases associated with thrombosis inflammation, such as isohemia stroke, aging, heart disease, cancer, and even COVID-19.
    " () Source: Sickle cell target can treat COVID Source: Junaid Ansari et al. Targeting AnxA1/Fpr2/ALX Pathway Regulates Neutrophil Function Promoting Thrombo-Inflammation Resolution in Sickle Cell Disease, Blood (2021). DOI: 10.1182/blood.2020009166
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.